NO20062885L - Terapeufiske anti-IGFR1-antistoffkombinasjoner - Google Patents
Terapeufiske anti-IGFR1-antistoffkombinasjonerInfo
- Publication number
- NO20062885L NO20062885L NO20062885A NO20062885A NO20062885L NO 20062885 L NO20062885 L NO 20062885L NO 20062885 A NO20062885 A NO 20062885A NO 20062885 A NO20062885 A NO 20062885A NO 20062885 L NO20062885 L NO 20062885L
- Authority
- NO
- Norway
- Prior art keywords
- therapeutic anti
- antibody combinations
- igfr1 antibody
- combinations
- igfr1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer kombinasjoner som omfatter en bindende sammensetning, f.eks. et anfi-IGFR1-antistoff, sammen med et kjemoterapeutisk middel. Fremgangsmåter for anvendelse av kombinasjonene for behandling av medisinske tilstander, feks. kreft, tilveiebringes også.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52473203P | 2003-11-21 | 2003-11-21 | |
PCT/US2004/038842 WO2005052005A1 (en) | 2003-11-21 | 2004-11-19 | Anti-igfr1 antibody therapeutic combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062885L true NO20062885L (no) | 2006-08-18 |
Family
ID=34632927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062885A NO20062885L (no) | 2003-11-21 | 2006-06-20 | Terapeufiske anti-IGFR1-antistoffkombinasjoner |
Country Status (21)
Country | Link |
---|---|
US (1) | US8017735B2 (no) |
EP (2) | EP1689782B1 (no) |
JP (2) | JP2007532478A (no) |
KR (1) | KR20060100432A (no) |
CN (1) | CN1906214B (no) |
AR (1) | AR046639A1 (no) |
AT (1) | ATE465180T1 (no) |
AU (2) | AU2004292554B2 (no) |
CA (1) | CA2546664A1 (no) |
DE (1) | DE602004026768D1 (no) |
ES (1) | ES2343328T3 (no) |
HK (1) | HK1087131A1 (no) |
IL (1) | IL175773A0 (no) |
NO (1) | NO20062885L (no) |
NZ (1) | NZ547266A (no) |
PE (1) | PE20050928A1 (no) |
PL (1) | PL380527A1 (no) |
SG (1) | SG160412A1 (no) |
TW (1) | TW200526684A (no) |
WO (1) | WO2005052005A1 (no) |
ZA (1) | ZA200604074B (no) |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101086533B1 (ko) | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
ATE493433T1 (de) | 2002-09-11 | 2011-01-15 | Genentech Inc | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
CA2524305C (en) | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
ATE514783T1 (de) | 2003-11-12 | 2011-07-15 | Schering Corp | Plasmidsystem zur expression mehrerer gene |
AP2139A (en) | 2004-04-02 | 2010-08-21 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors. |
JP2008521907A (ja) | 2004-12-03 | 2008-06-26 | シェーリング コーポレイション | 抗igf1r治療について患者を予め選択するためのバイオマーカー |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
CA2592543A1 (en) * | 2004-12-31 | 2006-07-13 | Aventis Pharmaceuticals Inc. | Use of selected compounds for protection of neurones and oligodendrocytes in the treatment of multiple sclerosis |
CA2596714C (en) | 2005-02-03 | 2014-06-17 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
EP1879587A2 (en) * | 2005-04-15 | 2008-01-23 | Schering Corporation | Methods and compositions for treating or preventing cancer |
NZ564098A (en) * | 2005-06-15 | 2010-04-30 | Schering Corp | Anti-IGF1R antibody formulations |
CA2612449A1 (en) | 2005-06-17 | 2006-12-28 | Imclone Systems Incorporated | Receptor antagonists for treatment of metastatic bone cancer |
FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
EP1926996B1 (en) | 2005-09-20 | 2011-11-09 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
DE602006015837D1 (de) * | 2005-10-14 | 2010-09-09 | Janssen Pharmaceutica Nv | Formulierungen von tipifarnib zur intravenösen verabreichung |
WO2007056118A1 (en) * | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
EP1984011A4 (en) | 2006-02-03 | 2010-08-18 | Imclone Llc | ANTAGONISTS OF IGF-IR AS ADJUVANTS FOR THE TREATMENT OF PROSTATE CANCER |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
JP5399900B2 (ja) * | 2006-06-30 | 2014-01-29 | メルク・シャープ・アンド・ドーム・コーポレーション | Igfbp2インヒビター |
EP2121018A2 (en) * | 2006-12-13 | 2009-11-25 | Schering Corporation | Treating cancer with anti-igf1r antibody 19d12=sch 717454 |
US20100166747A1 (en) * | 2007-03-02 | 2010-07-01 | Beltran Pedro J | Methods and compositions for treating tumor diseases |
EP2173338A1 (en) * | 2007-07-06 | 2010-04-14 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy |
JP5570989B2 (ja) * | 2007-08-31 | 2014-08-13 | アムジエン・インコーポレーテツド | 固体タンパク質製剤 |
AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
US7939272B2 (en) | 2007-10-03 | 2011-05-10 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US8048621B2 (en) | 2007-10-03 | 2011-11-01 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
EP2219602A1 (en) | 2007-11-15 | 2010-08-25 | Amgen, Inc | Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
US20110046144A1 (en) * | 2008-01-18 | 2011-02-24 | Mulvihill Mark J | Imidazopyrazinol derivatives for the treatment of cancers |
EP2259797A2 (en) * | 2008-03-25 | 2010-12-15 | Schering Corporation | Methods for treating or preventing colorectal cancer |
EP3208612B1 (en) * | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
JP2011519868A (ja) * | 2008-05-05 | 2011-07-14 | シェーリング コーポレイション | 癌を処置するための化学療法剤の連続投与 |
ES2431355T3 (es) | 2008-06-17 | 2013-11-26 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
ES2968373T3 (es) | 2008-08-04 | 2024-05-09 | Wyeth Llc | Combinaciones antineoplásicas de neratinib y capecitabina |
CA2742986C (en) * | 2008-11-07 | 2015-03-31 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
EP2236139A1 (en) | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor |
EP4218760A3 (en) | 2009-04-06 | 2023-08-16 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
JP2012524119A (ja) | 2009-04-20 | 2012-10-11 | オーエスアイ・ファーマシューティカルズ,エルエルシー | C−ピラジン−メチルアミンの調製 |
WO2010127069A1 (en) * | 2009-04-29 | 2010-11-04 | Schering Corporation | Antibody purification |
JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
US8609675B2 (en) | 2009-07-02 | 2013-12-17 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds as novel mTOR inhibitors |
WO2011028638A1 (en) | 2009-09-04 | 2011-03-10 | Schering Corporation | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
WO2011050333A1 (en) | 2009-10-23 | 2011-04-28 | Amgen Inc. | Vial adapter and system |
CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
JP2013527748A (ja) | 2010-03-03 | 2013-07-04 | オーエスアイ・ファーマシューティカルズ,エルエルシー | インスリン様増殖因子1受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー |
EA024052B1 (ru) | 2010-06-07 | 2016-08-31 | Эмджен Инк. | Устройство для доставки лекарственного средства |
EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
AU2011312128B2 (en) * | 2010-10-07 | 2015-12-10 | University Of Louisville Research Foundation, Inc. | IGF-1 dependent modulation of VSELs |
CA2825894C (en) | 2011-02-02 | 2021-11-30 | Amgen Inc. | Prognosis of cancer using a circulating biomarker |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
PL2699293T3 (pl) | 2011-04-20 | 2019-08-30 | Amgen Inc. | Urządzenie do wstrzykiwania automatycznego |
CA2833009A1 (en) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Insulin-like growth factor-1 receptor inhibitors |
EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
EP2736338B1 (en) | 2011-07-26 | 2019-01-23 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS |
EP3744371A1 (en) | 2011-10-14 | 2020-12-02 | Amgen, Inc | Injector and method of assembly |
JP6268097B2 (ja) | 2011-11-11 | 2018-01-24 | デューク・ユニヴァーシティ | 固形腫瘍治療のための併用薬物療法 |
EP2631653A1 (en) | 2012-02-24 | 2013-08-28 | Charité - Universitätsmedizin Berlin | Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
US9603844B2 (en) * | 2012-10-22 | 2017-03-28 | Georgetown University | Compositions and methods for treating mammary tumors |
CA2884887C (en) | 2012-11-21 | 2023-09-12 | Amgen Inc. | Drug delivery device including insertion member and reservoir |
EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | CANCER THERAPY |
TWI639449B (zh) | 2013-03-15 | 2018-11-01 | 美商安美基公司 | 用於注射器之匣盒 |
WO2014144096A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
US10850037B2 (en) | 2013-03-22 | 2020-12-01 | Amgen Inc. | Injector and method of assembly |
BR112016000853A2 (pt) | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
AU2014340174B2 (en) | 2013-10-24 | 2019-09-12 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
JP7086520B2 (ja) | 2013-10-24 | 2022-06-20 | アムジエン・インコーポレーテツド | インジェクター及び組み立ての方法 |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
EP3139977B1 (en) | 2014-05-07 | 2021-02-17 | Amgen Inc. | Autoinjector with shock reducing elements |
WO2015187799A1 (en) | 2014-06-03 | 2015-12-10 | Amgen Inc. | Systems and methods for remotely processing data collected by a drug delivery device |
JP6766040B2 (ja) | 2014-10-14 | 2020-10-07 | アムジエン・インコーポレーテツド | 視覚および可聴インジケータを備える薬剤注射装置 |
US11357916B2 (en) | 2014-12-19 | 2022-06-14 | Amgen Inc. | Drug delivery device with live button or user interface field |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
CA2976935C (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
WO2016138434A1 (en) | 2015-02-27 | 2016-09-01 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
US10946095B2 (en) | 2015-09-02 | 2021-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT) |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
BR112018005862A2 (pt) | 2015-09-25 | 2018-10-16 | Genentech, Inc. | anticorpos, anticorpos isolados, polinucleotídeo, vetor, célula hospedeira, método de produção do anticorpo, imunoconjugado, composição, usos dos anticorpos, métodos para tratar ou retardar a progressão de um câncer e de uma doença e para aumentar, potencializar ou estimular uma resposta ou função imune e kit |
ES2755717T3 (es) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinyector con tapa de señalización |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
DK3429663T3 (da) | 2016-03-15 | 2020-09-28 | Amgen Inc | Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
ES2959783T3 (es) | 2016-05-13 | 2024-02-28 | Amgen Inc | Conjunto de cubierta protectora de vial |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
WO2018152073A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
US11752258B2 (en) | 2017-02-17 | 2023-09-12 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
AU2018231107B2 (en) | 2017-03-06 | 2023-04-20 | Amgen Inc. | Drug delivery device with activation prevention feature |
EP3592402A1 (en) | 2017-03-07 | 2020-01-15 | Amgen Inc. | Needle insertion by overpressure |
EP3592404A1 (en) | 2017-03-09 | 2020-01-15 | Amgen Inc. | Insertion mechanism for drug delivery device |
CA3052676A1 (en) | 2017-03-28 | 2018-10-04 | Amgen Inc. | Plunger rod and syringe assembly system and method |
WO2018226515A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
WO2018236619A1 (en) | 2017-06-22 | 2018-12-27 | Amgen Inc. | REDUCING THE IMPACTS / IMPACTS OF ACTIVATION OF A DEVICE |
MA49461A (fr) | 2017-06-23 | 2020-04-29 | Amgen Inc | Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur |
ES2972207T3 (es) | 2017-07-14 | 2024-06-11 | Amgen Inc | Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble |
EP3655063A1 (en) | 2017-07-21 | 2020-05-27 | Amgen Inc. | Gas permeable sealing member for drug container and methods of assembly |
JP2020528296A (ja) | 2017-07-25 | 2020-09-24 | アムジエン・インコーポレーテツド | ギヤモジュールを有する薬物送達デバイス及び関連する組立方法 |
US11484648B2 (en) | 2017-07-25 | 2022-11-01 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019046600A1 (en) | 2017-08-30 | 2019-03-07 | Amgen Inc. | INSULIN-RELATED GROWTH FACTOR 1 RECEPTOR BINDING PROTEINS (IGF-1R) AND METHODS OF USE |
MA50611A (fr) | 2017-10-04 | 2020-08-12 | Amgen Inc | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
US11305026B2 (en) | 2017-11-03 | 2022-04-19 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
US20200261648A1 (en) | 2017-11-06 | 2020-08-20 | Amgen Inc. | Drug delivery device with placement and flow sensing |
WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
MX2020004736A (es) | 2017-11-10 | 2020-08-13 | Amgen Inc | Embolos para dispositivos de administracion de farmacos. |
EP3710090A1 (en) | 2017-11-16 | 2020-09-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
CA3084486A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Autoinjector with stall and end point detection |
WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
MX2021000749A (es) | 2018-07-24 | 2021-03-29 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
EP3826701A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
US20210228797A1 (en) | 2018-07-31 | 2021-07-29 | Amgen Inc. | Fluid path assembly for a drug delivery device |
CA3106452A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
IL281469B1 (en) | 2018-09-28 | 2024-04-01 | Amgen Inc | Assembling a memory alloy ejector activation assembly for a drug delivery device |
CN117159846A (zh) | 2018-10-02 | 2023-12-05 | 安进公司 | 具有内部力传递的用于药物递送的注射系统 |
WO2020072846A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
EA202191038A1 (ru) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | Способ платформенной сборки для устройства доставки лекарственного средства |
EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
WO2020091956A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
AU2019370159A1 (en) | 2018-11-01 | 2021-04-22 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
CN113286591A (zh) * | 2018-11-01 | 2021-08-20 | 库拉肿瘤学公司 | 用法尼基转移酶抑制剂治疗癌症的方法 |
US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
AU2020263289A1 (en) | 2019-04-24 | 2021-09-16 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
JP2022545227A (ja) | 2019-08-23 | 2022-10-26 | アムジエン・インコーポレーテツド | 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法 |
US20230310436A1 (en) * | 2019-10-09 | 2023-10-05 | Cothera Bioscience, Inc. | Combination therapy for cancers with kras mutation |
US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
CN114917329B (zh) * | 2021-02-11 | 2023-07-21 | 兰州大学第二医院 | 抗cd87抗体与抗pd1抗体联合治疗胃癌 |
BR112023024278A2 (pt) | 2021-05-21 | 2024-01-30 | Amgen Inc | Método de otimizar uma receita de enchimento para um recipiente de fármacos |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260291A (en) * | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US4543439A (en) * | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
JPS6019790A (ja) * | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
CA2076975A1 (en) | 1990-02-28 | 1991-08-29 | Kevin W. Moore | Mammalian expression vectors |
CA2078689C (en) | 1990-03-20 | 2003-02-11 | Sherie L. Morrison | Chimeric antibodies with receptor binding ligands in place of their constant region |
US6300129B1 (en) * | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5198340A (en) * | 1991-01-17 | 1993-03-30 | Genentech, Inc. | Assay for free igf-i, igf-ii, and gh levels in body fluids |
WO1993012808A1 (en) * | 1991-12-20 | 1993-07-08 | Shuji Nakamura | A method for treating kaposi's sarcoma and blocking or inhibiting vascular permeability |
US5262308A (en) * | 1992-01-28 | 1993-11-16 | Thomas Jefferson University | Cell lines which constitutively express IGF-1 and IGF-1 R |
DE69328430T2 (de) * | 1992-07-27 | 2001-01-25 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
JPH08508409A (ja) * | 1993-04-06 | 1996-09-10 | シーダーズ − サイナイ メディカル センター | 変異インスリン様増殖因子▲i▼受容体サブユニットおよびそれらの使用方法 |
US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US20020022023A1 (en) * | 1999-01-15 | 2002-02-21 | Axel Ullrich | Treatment of diabetes mellitus and insulin receptor signal transduction |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
EP0861267A4 (en) * | 1995-11-14 | 2000-02-02 | Univ Jefferson | INDUCTION AND RESISTANCE TO TUMOR GROWTH BY MEANS OF SOLUBLE IGF-1 |
US6346390B1 (en) * | 1996-03-08 | 2002-02-12 | Receptron, Inc. | Receptor derived peptides involved in modulation of response to ligand binding |
US5958872A (en) * | 1996-04-01 | 1999-09-28 | Apoptosis Technology, Inc. | Active survival domains of IGF-IR and methods of use |
US20020107187A1 (en) * | 1996-05-22 | 2002-08-08 | Kingston David J. | Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof |
AUPN999096A0 (en) | 1996-05-22 | 1996-06-13 | Northstar Biologicals Pty Ltd | Peptides, antibodies, vaccines & uses thereof |
ES2136583T1 (es) | 1996-10-18 | 1999-12-01 | Canji Inc | Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa. |
US20020155095A1 (en) * | 1996-10-18 | 2002-10-24 | Tattanahalli L. Nagabhushan | Methods and compositions for delivery and expression of interferon-a nucleic acids |
WO1998022092A1 (en) | 1996-11-22 | 1998-05-28 | The Regents Of The University Of California | Transport of liposomes across the blood-brain barrier |
US6294330B1 (en) * | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
US6121416A (en) * | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
DE19719001C2 (de) | 1997-05-06 | 2001-05-10 | Schuetzdeller Angelika | Verfahren zum immunologisch-funktionalen Nachweis biologisch aktiver Insulin-Like Growth Factor Binding Proteine oder löslicher Insulin-Like Growth Factor - Rezeptoren im Immunoassay |
EP1030684A4 (en) | 1997-11-14 | 2004-09-15 | Euro Celtique Sa | MODIFIED ANTIBODIES WITH IMPROVED CAPACITY TO TRIGGER ANTI-IDIOTYPE RESPONSE |
EP1034188B1 (en) | 1997-11-27 | 2006-06-07 | Commonwealth Scientific And Industrial Research Organisation | Method of designing agonists and antagonists to igf receptor (1-462) |
EP1064015A2 (en) | 1998-02-24 | 2001-01-03 | Receptron, Inc. | Receptor derived peptides as modulators of receptor activity |
KR20010071271A (ko) | 1998-05-15 | 2001-07-28 | 존 비. 랜디스 | 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법 |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US20030236190A1 (en) * | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
US6875741B2 (en) * | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
US7173005B2 (en) * | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
EP1121437B1 (en) | 1998-10-15 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Metastatic breast and colon cancer regulated genes |
WO2000050067A1 (en) | 1999-02-26 | 2000-08-31 | Saltech I Göteborg Ab | Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1 |
US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
WO2000066125A1 (en) * | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
WO2000069454A1 (en) | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression of endogenous igfbp-2 to inhibit cancer |
WO2001007084A1 (en) | 1999-07-23 | 2001-02-01 | Regents Of The University Of California | Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery |
WO2001030964A2 (en) | 1999-10-22 | 2001-05-03 | Lifespan Biosciences, Inc. | Anti-cancer nucleic acid and protein targets |
AU2135001A (en) * | 1999-12-15 | 2001-06-25 | Mcgill University | Targeting of endosomal growth factor processing as anti-cancer therapy |
GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
WO2001070930A2 (en) | 2000-03-21 | 2001-09-27 | University Of South Florida | Growth factor binding molecules |
WO2001070268A1 (en) | 2000-03-22 | 2001-09-27 | Glaxo Group Limited | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
EP1268510A4 (en) | 2000-03-31 | 2003-05-28 | Hyseq Inc | METHOD AND MATERIALS REGARDING INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN POLYPEPTIDES AND POLYNUCLEOTIDES |
US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
GB0012233D0 (en) | 2000-05-19 | 2000-07-12 | Devgen Nv | Vector constructs |
US20030165502A1 (en) * | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
US7329745B2 (en) * | 2000-06-13 | 2008-02-12 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
AU2001277531A1 (en) | 2000-07-10 | 2002-01-21 | Novartis Ag | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
US20020164333A1 (en) * | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
US8153121B2 (en) * | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
CN1479872A (zh) | 2000-10-12 | 2004-03-03 | 艾科斯有限公司 | 调节含有变构调节位点的α/β蛋白的配体结合/酶活性的物质和方法 |
AU2002236572A1 (en) * | 2000-11-03 | 2002-05-21 | Board Of Regents, The University Of Texas System | Methods for detecting the efficacy of anticancer treatments |
US20020111290A1 (en) | 2000-12-01 | 2002-08-15 | Bernhard Homey | Uses of mammalian genes and related reagents |
SV2007000775A (es) * | 2001-01-05 | 2007-03-15 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ES2330201T3 (es) | 2001-01-26 | 2009-12-07 | Selexis S.A. | Regiones de union a la matriz y metodos para el uso de las mismas. |
WO2002072780A2 (en) | 2001-03-14 | 2002-09-19 | Genentech, Inc. | Igf antagonist peptides |
WO2002087618A1 (fr) * | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
US7498029B2 (en) * | 2001-05-01 | 2009-03-03 | The General Hospital Corporation | Photoimmunotherapies for cancer using combination therapies |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
AUPR870501A0 (en) | 2001-11-07 | 2001-11-29 | Biotech Research Ventures Pte Limited | Composition containing a flavonoid glycone and method for using same as anti-proliferative |
US7553485B2 (en) * | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
FR2834900B1 (fr) | 2002-01-18 | 2005-07-01 | Pf Medicament | Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications |
FR2834991B1 (fr) | 2002-01-18 | 2004-12-31 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
EP1461359B1 (fr) | 2002-01-18 | 2007-03-21 | Pierre Fabre Medicament | Anticorps anti-igf-ir et leurs applications |
US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
FR2834990A1 (fr) | 2002-01-18 | 2003-07-25 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
WO2003088910A2 (en) | 2002-04-15 | 2003-10-30 | Rigel Pharmaceuticals, Inc. | Methods of assaying for cell cycle modulators |
US7655397B2 (en) * | 2002-04-25 | 2010-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers |
US7485314B2 (en) * | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
US20050276812A1 (en) * | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
KR101086533B1 (ko) * | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US20040086511A1 (en) * | 2002-07-12 | 2004-05-06 | The Johns Hopkins University | Neuronal gene expression patterns |
US20040142381A1 (en) * | 2002-07-31 | 2004-07-22 | Hubbard Stevan R. | Methods for designing IGF1 receptor modulators for therapeutics |
US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
US20030138430A1 (en) * | 2002-09-20 | 2003-07-24 | Stimmel Julie Beth | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
ES2383014T3 (es) * | 2003-04-02 | 2012-06-15 | F. Hoffmann-La Roche Ag | Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
CA2524305C (en) | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
PL2644206T3 (pl) * | 2003-05-23 | 2019-09-30 | Nektar Therapeutics | Pochodne PEG zawierające dwa łańcuchy PEG |
AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
TW200510384A (en) * | 2003-08-07 | 2005-03-16 | Schering Corp | Novel farnesyl protein transferase inhibitors as antitumor agents |
UA85058C2 (ru) * | 2003-08-13 | 2008-12-25 | Пфайзер Продактс Инк. | Модифицированное моноклональное антитело человека, которое специфически связывается с рецептором подобного к инсулину фактора роста i человека (igf-ir) |
ATE514783T1 (de) * | 2003-11-12 | 2011-07-15 | Schering Corp | Plasmidsystem zur expression mehrerer gene |
EP1796711A2 (en) * | 2004-04-22 | 2007-06-20 | Oregon Health and Science University | Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors |
BRPI0511065A (pt) | 2004-06-04 | 2007-12-26 | Pfizer Prod Inc | método para tratar crescimento de célula anormal |
EP2322217A3 (en) * | 2004-07-16 | 2011-09-28 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
JP2008521907A (ja) * | 2004-12-03 | 2008-06-26 | シェーリング コーポレイション | 抗igf1r治療について患者を予め選択するためのバイオマーカー |
EP1879587A2 (en) * | 2005-04-15 | 2008-01-23 | Schering Corporation | Methods and compositions for treating or preventing cancer |
NZ564098A (en) * | 2005-06-15 | 2010-04-30 | Schering Corp | Anti-IGF1R antibody formulations |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007093008A1 (en) | 2006-02-17 | 2007-08-23 | Adelaide Research & Innovation Pty Ltd | Antibodies to insulin-like growth factor i receptor |
JP5399900B2 (ja) * | 2006-06-30 | 2014-01-29 | メルク・シャープ・アンド・ドーム・コーポレーション | Igfbp2インヒビター |
-
2004
- 2004-11-18 PE PE2004001131A patent/PE20050928A1/es not_active Application Discontinuation
- 2004-11-18 TW TW093135439A patent/TW200526684A/zh unknown
- 2004-11-18 AR ARP040104263A patent/AR046639A1/es unknown
- 2004-11-19 KR KR1020067009791A patent/KR20060100432A/ko active IP Right Grant
- 2004-11-19 CA CA002546664A patent/CA2546664A1/en not_active Abandoned
- 2004-11-19 DE DE602004026768T patent/DE602004026768D1/de active Active
- 2004-11-19 WO PCT/US2004/038842 patent/WO2005052005A1/en active Application Filing
- 2004-11-19 AT AT04811545T patent/ATE465180T1/de not_active IP Right Cessation
- 2004-11-19 EP EP04811545A patent/EP1689782B1/en active Active
- 2004-11-19 EP EP10160260.5A patent/EP2230254B1/en active Active
- 2004-11-19 AU AU2004292554A patent/AU2004292554B2/en not_active Ceased
- 2004-11-19 SG SG201001853-9A patent/SG160412A1/en unknown
- 2004-11-19 US US10/993,395 patent/US8017735B2/en not_active Expired - Fee Related
- 2004-11-19 JP JP2006541410A patent/JP2007532478A/ja not_active Ceased
- 2004-11-19 PL PL380527A patent/PL380527A1/pl unknown
- 2004-11-19 NZ NZ547266A patent/NZ547266A/en not_active IP Right Cessation
- 2004-11-19 CN CN2004800408015A patent/CN1906214B/zh not_active Expired - Fee Related
- 2004-11-19 ES ES04811545T patent/ES2343328T3/es active Active
-
2006
- 2006-05-18 IL IL175773A patent/IL175773A0/en unknown
- 2006-05-19 ZA ZA200604074A patent/ZA200604074B/xx unknown
- 2006-06-20 NO NO20062885A patent/NO20062885L/no not_active Application Discontinuation
- 2006-08-19 HK HK06109205.6A patent/HK1087131A1/xx not_active IP Right Cessation
-
2009
- 2009-08-28 AU AU2009212853A patent/AU2009212853A1/en not_active Abandoned
-
2011
- 2011-08-26 JP JP2011185153A patent/JP2011236253A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2009212853A1 (en) | 2009-09-24 |
EP1689782B1 (en) | 2010-04-21 |
AR046639A1 (es) | 2005-12-14 |
CN1906214A (zh) | 2007-01-31 |
HK1087131A1 (en) | 2006-10-06 |
JP2007532478A (ja) | 2007-11-15 |
EP1689782A1 (en) | 2006-08-16 |
KR20060100432A (ko) | 2006-09-20 |
ES2343328T3 (es) | 2010-07-28 |
US8017735B2 (en) | 2011-09-13 |
SG160412A1 (en) | 2010-04-29 |
AU2004292554B2 (en) | 2009-05-28 |
ZA200604074B (en) | 2007-03-28 |
CN1906214B (zh) | 2012-06-20 |
DE602004026768D1 (de) | 2010-06-02 |
TW200526684A (en) | 2005-08-16 |
WO2005052005A1 (en) | 2005-06-09 |
EP2230254A3 (en) | 2010-10-27 |
ATE465180T1 (de) | 2010-05-15 |
PL380527A1 (pl) | 2007-02-19 |
IL175773A0 (en) | 2006-09-05 |
AU2004292554A1 (en) | 2005-06-09 |
CA2546664A1 (en) | 2005-06-09 |
JP2011236253A (ja) | 2011-11-24 |
US20050136063A1 (en) | 2005-06-23 |
PE20050928A1 (es) | 2005-11-08 |
EP2230254B1 (en) | 2013-05-15 |
EP2230254A2 (en) | 2010-09-22 |
NZ547266A (en) | 2009-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062885L (no) | Terapeufiske anti-IGFR1-antistoffkombinasjoner | |
NO20070782L (no) | Tetrapeptidanaloger. | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
IL244803A0 (en) | Human anti-beta7 antibodies and their use | |
BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
SE0301700D0 (sv) | Novel compounds | |
DE50310516D1 (de) | Fredericamycin-derivate | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
TW200528117A (en) | Methods and reagents for the treatment of proliferative diseases | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
EA200601555A1 (ru) | Замещенные индазол-о-глюкозиды | |
EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
DK1446012T3 (da) | Bakteriolytisk kombinationsterapi til behandling af tumorer | |
UA85559C2 (en) | Aminobenzophenone compounds | |
DK2054418T3 (da) | Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer | |
NO20072179L (no) | Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer | |
WO2005085188A3 (en) | Compounds and methods for anti-tumor therapy | |
ATE542796T1 (de) | N-sulfonylcarboximidamidverbindungen als apoptosepromotoren | |
DE60228484D1 (de) | Cytotoxische mittel | |
EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
WO2005007123A3 (en) | Pin1-modulating compounds and methods of use thereof | |
SE0301650D0 (sv) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |